Goldman Sachs
NXTM

Goldman Sachs’s NxStage Medical Inc. NXTM Stock Holding History

Goldman Sachs’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-846,876
Closed -$24.2M – 5635
2018
Q4 		$24.2M Buy
846,876
+15,691
+2% +$446K 0.01% 1645
2018
Q3 		$23.2M Buy
831,185
+76,862
+10% +$2.16M 0.01% 1814
2018
Q2 		$21M Sell
754,323
-319,563
-30% -$8.57M 0.01% 1833
2018
Q1 		$26.7M Buy
1,073,886
+125,491
+13% +$3.05M 0.01% 1614
2017
Q4 		$23M Sell
948,395
-325,069
-26% -$8.56M 0.01% 1835
2017
Q3 		$35.1M Buy
1,273,464
+1,173,012
+1,168% +$31.3M 0.01% 1532
2017
Q2 		$2.52M Buy
100,452
+16,817
+20% +$416K ﹤0.01% 3650
2017
Q1 		$2.24M Buy
83,635
+40,071
+92% +$1.11M ﹤0.01% 3632
2016
Q4 		$1.14M Sell
43,564
-461,851
-91% -$11.4M ﹤0.01% 4332
2016
Q3 		$12.6M Buy
505,415
+404,642
+402% +$9.43M ﹤0.01% 2260
2016
Q2 		$2.19M Sell
100,773
-5,070
-5% -$90.5K ﹤0.01% 3540
2016
Q1 		$1.59M Buy
105,843
+72,332
+216% +$1.21M ﹤0.01% 3691
2015
Q4 		$734K Sell
33,511
-5,325
-14% -$99.2K ﹤0.01% 4593
2015
Q3 		$613K Sell
38,836
-78,580
-67% -$1.26M ﹤0.01% 4940
2015
Q2 		$1.68M Buy
117,416
+77,819
+197% +$1.32M ﹤0.01% 4020
2015
Q1 		$685K Buy
39,597
+28,648
+262% +$506K ﹤0.01% 4823
2014
Q4 		$196K Sell
10,949
-1,156
-10% -$18.6K ﹤0.01% 6170
2014
Q3 		$159K Sell
12,105
-2,260
-16% -$30.4K ﹤0.01% 6341
2014
Q2 		$206K Sell
14,365
-1,394
-9% -$18.2K ﹤0.01% 6183
2014
Q1 		$201K Buy
+15,759
New +$206K ﹤0.01% 6080
2013
Q4 		– Sell
-7,347
Closed -$97K – 6878
2013
Q3 		$97K Sell
7,347
-38,606
-84% -$506K ﹤0.01% 6166
2013
Q2 		$656K Buy
+45,953
New +$578K ﹤0.01% 4724

Other funds holding NXTM

TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs's NXTM Position: Q1 2019 in Review

Goldman Sachs sold out of NxStage Medical Inc. (NXTM) in Q1 2019, closing a stake of 846,876 shares — an estimated $24.2M sold.

Goldman Sachs first reported a position in NXTM in Q2 2013 and held it in 22 quarters. The position peaked at $35.1M in Q3 2017. 1 fund tracked by Wall St. Rank holds NXTM as of Q1 2019.

  • Goldman Sachs reported no remaining NxStage Medical Inc. position as of Q1 2019 after selling out during the quarter.
  • Goldman Sachs sold 846,876 NxStage Medical Inc. shares in Q1 2019, an estimated $24.2M.
  • Goldman Sachs first reported a position in NxStage Medical Inc. in Q2 2013 and held it in 22 quarters.
  • Goldman Sachs's NxStage Medical Inc. position peaked at $35.1M in Q3 2017.
  • 1 fund tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2019.

Based on Goldman Sachs's 13F filing for Q1 2019, filed 15 May 2019.